Alpha Cancer Technologies (ACT) to Present at the 3rd Annual Next-Generation Conjugates Summit
Press ReleaseToronto, Canada, January 22, 2024 — Alpha Cancer Technologies (ACT), a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunomodulation therapies based